Oligonucleotide ADC Design and Development – An Emerging Field Building on the Success of ADCs in Cancer

Published on April 4, 2022

Create new potential in the ADC oncology space with deep insight and understanding into the innovative field of oligonucleotide bioconjugates,  focusing upon their design, development, analysis and manufacture.

The post Oligonucleotide ADC Design and Development – An Emerging Field Building on the Success of ADCs in Cancer appeared first on abzena.

Continue reading on website
Other news

ADC Developability for Successful Lead Candidate Selection

April 4, 2022
Inform your ADC lead candidate selection with our insights into the best practices for developing and applying suitable analytical workflows and the considerations and mitigation of risks for overall best in class bioconjugate design.The post ADC Developability for Successful Lead Candidate Selection appeared first on abzena.

Addressing the Challenges of Next-Generation Antibody-Drug Conjugate Medicines

April 4, 2022
Access and leverage deep industry knowledge into some of the key strategies in support appropriate target product profiling for the development of next-generation Antibody-Drug Conjugates (ADCs).The post Addressing the Challenges of Next-Generation Antibody-Drug Conjugate Medicines appeared first on abzena.